Hepatosplenic T Cell Lymphoma C1333984
A rare, aggressive cancer of immune cells affecting the liver and spleen, typically seen in young to middle-aged adults. Requires intensive chemotherapy with a generally poor prognosis.
Key facts at a glance
- ICD-10
- C86.10, C86.11
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Hepatomegaly
(hepatobiliary)Splenomegaly
(hematologic)Fever
(general)Severe anemia due to bone marrow infiltration
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Drug therapy and clinical monitoring
Active treatment with regular monitoring by a healthcare provider is recommended.
Combination chemotherapy regimen
Intensive chemotherapy using multi-agent protocols designed to target and eliminate malignant T-cells. This approach forms the cornerstone of initial treatment for this aggressive lymphoma subtype.
Allogeneic stem cell transplantation
High-dose chemotherapy followed by infusion of healthy donor stem cells to restore bone marrow function and provide graft-versus-lymphoma effect. This is potentially curative for eligible patients who achieve remission.
Additional treatment options
Immunotherapy with histone deacetylase inhibitors
Targeted biological therapy using agents that modify gene expression in cancer cells, potentially slowing disease progression when standard therapies are ineffective or as maintenance.
medicationClinical trial enrollment
Participation in investigational studies evaluating novel therapies including new immunotherapeutic agents, targeted small molecules, or cellular therapy approaches that may offer benefit beyond standard treatments.
procedureSurveillance imaging and tumor markers
Regular monitoring with CT, PET-CT, or MRI scans along with relevant laboratory markers to assess treatment response, detect recurrence early, and guide treatment decisions throughout the disease course.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Hepatosplenic T Cell Lymphoma C1333984?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Hepatosplenic T Cell Lymphoma C1333984. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy